Singulair instructions for use, contraindications, side effects, reviews

Singulair is a drug (tablets) that belongs to the group of drugs for the treatment of bronchial asthma. Important features of the drug from the instructions for use:

How to dissolve vascular plaques, normalize blood circulation, blood pressure and forget the way to the pharmacy

• Sold only with a doctor's prescription
• During pregnancy: with caution
• When breastfeeding: with caution
• In childhood: with caution
• For liver dysfunction: with caution
• If kidney function is impaired: you can
• In old age: possible

Compound

The active ingredient is montelukast.

Additional components of 4 mg tablets: hydroxypropylcellulose, mannitol, croscarmellose sodium, aspartame, MCC, red iron oxide, cherry flavor, magnesium stearate.

Pink 5 mg tablets contain the following excipients: mannitol, red iron oxide, hyprolose, aspartame, croscarmellose sodium, cherry flavor, MCC, magnesium stearate.

Film-coated tablets of 10 mg include additional components such as croscarmellose sodium, MCC, magnesium stearate, lactose, hyprolose. Shell composition: red iron oxide, yellow iron oxide, hyprolose, titanium dioxide, hypromellose, carnauba wax.

How to take Singulair, chew or swallow?

Singulair is a drug that is used to treat children and adults with various pathologies of the respiratory system. It has pronounced therapeutic properties and helps to cope even with advanced diseases. Feedback from parents about the effect of the medication is mostly positive, which proves its safety and effectiveness.

Release forms and composition of the drug

The pharmacological agent can be found on the shelves of almost every pharmacy. It is produced by many pharmaceutical companies in the form of tablets intended to be chewed. The tablets themselves are packaged in blisters of 8 pieces. An individual cardboard box may contain 2 such plates, as well as detailed instructions explaining the rules for using the medication.

The drug contains the substance montelukast as the main active component.

Singular for children

It also contains auxiliary ingredients:

• Microcrystalline cellulose.
• Aspartame.
• Beckons.
• Iron oxide.
• Titanium dioxide
• Magnesium stearate.
• Dye.
• Flavoring.

The amount of the main substance in tablets may vary. The most popular are tablets with a dosage of 4 and 5 mg, but a medicine with a dose of 10 mg is available, which in most cases is used for the treatment of adults.

Pharmacodynamics and pharmacokinetics

After ingestion, the drug is actively absorbed and begins to act, concentrating in the tissues of the bronchi. Montelukast acts on interleukin receptors in the epithelial tissue of the bronchi, which leads to the elimination of organ spasm and respiratory impairment.

Thanks to this, the patient’s condition improves not only in acute inflammatory pathologies, but also in advanced bronchial asthma. When a large amount of mucus is produced, pathogens are quickly removed from the bronchi and the process of restoration of the affected areas begins.

When the tablet is chewed, the active components enter the systemic circulation after some time and bind to blood proteins. The maximum plasma concentration is observed 2 hours after consumption. At the same time, one can note the most pronounced therapeutic effect, which lasts for 12-18 hours, depending on the characteristics of the patient’s body.

The bioavailability of the active substance of the composition is close to 75%. It is worth noting that taking it with food reduces the bioavailability rate by about 10%, but does not weaken the effectiveness of the drug. Metabolism of montelukast occurs in the liver, where the component breaks down into several substances.

It is worth noting that in patients with liver pathologies, there is a slowdown in the processing of the ingredient, as well as a slight weakening of the therapeutic effect. The period of evacuation of metabolites from the body is approximately 2 days. In patients with diseases of the gallbladder and ducts, this time is extended by several hours.

The main amount of breakdown products of the active component is excreted in bile, a small part is excreted in urine.

At what age can the drug be used?

Singulair for children (it is better to study reviews of the drug before using it) is used from 2 years of age. The drug is almost never prescribed to a child under 2 years of age.

Despite this, the pediatrician makes a decision individually in each case. The tablets have a pleasant taste and aroma, so children do not have problems with chewing.

Instructions for use, dosage

In this case, use should be carried out under adult supervision. The duration of treatment is approximately 2-4 weeks, depending on the severity of symptoms. Longer use is possible if symptoms do not subside.

Children from 6 to 14 years old are prescribed 5 mg of the drug in the evening for 3-6 weeks. For mild asthma, when attacks occur rarely, it is possible to stop using the medication. If the patient had attacks of bronchial asthma several days before starting treatment with Singulair, he took corticosteroids, the prescription of the drug is postponed for 5-7 days.

Adults and patients over 15 years of age are prescribed a single dose of 10 mg tablet. Be sure to take it in the evening or before bed. The therapeutic effect lasts throughout the night and almost all day.

Even if a pronounced remission occurs, it is recommended to use the medication for another week in order to prevent complications. The duration of treatment for adults is determined individually, taking into account the condition and the presence of complications.

It is recommended to use the product separately from food, which will increase the rate of absorption of the components, as well as maintain a normal level of bioavailability of the active substance.

Overdose

Singulair for children (patient reviews may be negative due to intolerance to the components of the composition) rarely leads to an overdose, provided it is used correctly. However, long-term use of an increased dose of medication certainly leads to the development of severe symptoms.

At the initial stage, all adverse reactions get worse. Nausea provokes vomiting, the headache intensifies, and discomfort in the muscles and joints leads to limited mobility. In addition, in adults with an overdose, hallucinations may appear, clouding of consciousness and an inability to navigate in space may occur.

The allergic reaction also gets worse. Children may develop acute urticaria or Quincke's edema. In the first case, large red spots appear on the skin; they provoke severe itching, forcing the child to scratch the affected areas. These scratches worsen the condition of the skin, damage the surface layer and can lead to tissue infection.

With angioedema, swelling of the mucous membranes of the upper palate and pharynx is usually observed, which leads to breathing problems and, if left untreated, can cause death.

The appearance of signs of overdose is considered a reason to stop using the drug and consult a doctor to receive symptomatic treatment.

Pharmacodynamics and pharmacokinetics

The active ingredient of the drug blocks cysteinyl leukotriene receptors of the respiratory tract epithelium. It inhibits bronchospasm caused by leukotriene LTD4 in the case of bronchial asthma.

Causes bronchodilation within a couple of hours after administration.

The drug is rapidly absorbed after oral administration. When taking the usual dosage of 10 mg, maximum plasma concentration is achieved after 3 hours. Bioavailability 64%. The product is safe and effective regardless of meals.

When taking 5 mg tablets after oral administration on an empty stomach, the maximum concentration is achieved after 2 hours. Bioavailability in this case is 73%, it decreases by 10% when used with food.

4 mg tablets are indicated for children 2-5 years old. The maximum concentration is reached after 2 hours.

About 99% of the active substance binds to plasma proteins. Actively metabolized. The main enzyme in metabolism is cytochrome P450 2C8. The participation of metabolites in the therapeutic effect is minimal.

Clearance of the active substance from plasma is approximately 45 ml/min. Excreted in bile almost completely along with metabolites.

In childhood

The medicine Singulair is approved for use by children aged 2 years and older in the form of chewable tablets strictly as prescribed by the attending physician. The daily dose of the medication depends on the age of the small patient:

Side effects

When taking the drug, the following negative side effects may occur:

• allergies: urticaria, anaphylaxis, rash, Quincke's edema, itchy skin;
• digestive system: nausea, dyspepsia, abdominal pain, vomiting, diarrhea;
• nervous system: nightmares, headache, drowsiness, tremor, depression, disorientation, excessive agitation or fatigue, paresthesia, hypoesthesia, hallucinations, increased irritability, aggressive behavior, insomnia, dizziness, lethargy;
• musculoskeletal system: myalgia, arthralgia;
• hepatobiliary system: increased levels of serum transaminases, hepatitis;
• other: increased likelihood of subcutaneous hemorrhages and increased bleeding, swelling, increased heart rate, thirst, discomfort, fever.

In rare cases, eosinophilic liver infiltrates, suicidal tendencies and seizures are possible.

In general, the medicine is well tolerated. Side effects, as a rule, do not require discontinuation of therapy.

Instructions for use of Singulair (Method and dosage)

The use of the drug for children is indicated under adult supervision.

In the case of allergic rhinitis and asthma, the instructions for Singulair indicate that you need to take 1 tablet of 4 mg once a day. In order to alleviate the manifestations of allergic rhinitis, the dosage regimen is selected individually.

For asthma, children 2-5 years old are given one chewable tablet of 4 mg every day in the evening.

The therapeutic effect of taking the medicine is achieved within 24 hours. It is recommended to continue taking the tablets even if your asthma is controlled.

The use of the drug as an alternative to low-dose inhaled corticosteroids for children with persistent mild asthma is possible only if there have been no recent serious asthma attacks that required corticosteroids, and also if patients cannot use inhaled corticosteroids. The patient's condition must be periodically assessed. If the desired effect is not achieved, another or additional anti-inflammatory therapy should be considered.

For those who are planning to take Singulair tablets, the instructions for use indicate that they can be added to bronchodilators.

In order to prevent bronchospasm, which is provoked by physical activity, the patient's condition must be assessed after 2-4 weeks of using the drug. If there is no sufficient effect, additional or other treatment should be considered.

Instructions for use of Singulair for adult patients and children over 15 years of age indicate that they need to take the medicine every day at a dosage of 10 mg 1 time. Children 6-14 years old are prescribed 5 mg per day.

Singulair chewable tablets 5 mg No. 28

A country

Russia, United Kingdom
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Compound

1 tablet contains: montelukast sodium 5.2 mg. Excipients: mannitol - 201.35 mg, microcrystalline cellulose - 66 mg, hyprolose (hydroxypropylcellulose) - 9 mg, red iron oxide - 0.45 mg, croscarmellose sodium - 9 mg, cherry flavor - 4.5 mg, aspartame - 1.5 mg, magnesium stearate - 3 mg. Chewable tablets are pink, round, biconvex, with the inscription “SINGULAIR” embossed on one side and “MSD 275” on the other.

pharmachologic effect

Leukotriene receptor antagonist. Cysteinyl leukotrienes LTC4, LTD4, LTE4 are strong mediators of inflammation - eicosanoids, which are secreted by various cells, including. mast cells and eosinophils. These important proasthmatic mediators bind to cysteinyl leukotriene receptors. Cysteinyl leukotriene receptors type I (CysLT1 receptors) are present in the human respiratory tract (including bronchial smooth muscle cells, macrophages) and other inflammatory cells (including eosinophils and some myeloid stem cells). Cysteinyl leukotrienes correlate with the pathophysiology of bronchial asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchospasm, increased mucus secretion, increased vascular permeability, and increased eosinophil counts. In allergic rhinitis, after exposure to an allergen, cysteinyl leukotrienes are released from proinflammatory cells of the nasal mucosa during the early and late phases of the allergic reaction, which is manifested by symptoms of allergic rhinitis. An intranasal test with cysteinyl leukotrienes demonstrated an increase in the resistance of the nasal airways and a symptom of nasal obstruction. Montelukast is a highly active drug when taken orally, which significantly improves inflammation in bronchial asthma. According to biochemical and pharmacological analysis, montelukast binds with high affinity and selectivity to CysLT1 receptors, without interacting with other pharmacologically important receptors in the respiratory tract (such as prostaglandin receptors, cholinergic or β-adrenergic receptors). Montelukast inhibits the physiological effect of cysteinyl leukotrienes LTC4, LTD4, LTE4 by binding to CysLT1 receptors without exerting a stimulating effect on these receptors. Montelukast inhibits CysLT receptors in the respiratory tract, as evidenced by the ability to block the development of bronchospasm in response to inhalation of LTD4 in patients with bronchial asthma. A dose of 5 mg is sufficient to relieve bronchospasm induced by LTD4. Montelukast causes bronchodilation within 2 hours after oral administration and can complement bronchodilation caused by β2-adrenergic agonists. The use of montelukast in doses of more than 10 mg/day once does not increase the effectiveness of the drug.

Indications for use

- prevention and long-term treatment of bronchial asthma in children aged 2 years and older: to control daytime and night symptoms of the disease; - relief of symptoms of allergic rhinitis in children aged 2 years and older.

Mode of application

Orally 1 time/day, regardless of meals. To treat bronchial asthma, Singulair® should be taken in the evening. When treating allergic rhinitis, the drug can be taken at any time of the day at the request of the patient. Patients with bronchial asthma and allergic rhinitis should take 1 tablet of Singulair® once a day in the evening. Children aged 2 to 5 years For bronchial asthma and/or allergic rhinitis rhinitis - 1 chewable tablet 4 mg per day. General recommendations The therapeutic effect of the drug Singulair® on indicators reflecting the course of bronchial asthma develops during the first day. The patient should continue to take Singulair® both during the period of achieving control of the symptoms of bronchial asthma, and during periods of exacerbation of bronchial asthma. For elderly patients, patients with renal failure, as well as patients with mild or moderate liver dysfunction, and also depending on gender no special dose selection is required. Prescribing the drug Singulair® simultaneously with other types of treatment for bronchial asthma The drug Singulair® can be added to the patient’s treatment with bronchodilators and inhaled corticosteroids.

Interaction

Singulair® can be prescribed together with other drugs traditionally used for the prevention and long-term treatment of bronchial asthma and/or treatment of allergic rhinitis. Montelukast at the recommended therapeutic dose did not have a clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin. When co-administered with phenobarbital, the AUC value of montelukast is reduced by approximately 40%. , but this does not require changes in the dosage regimen of Singulair®. In vitro studies have shown that montelukast inhibits the CYP2C8 isoenzyme. However, in an in vivo drug interaction study between montelukast and rosiglitazone (metabolized via the CYP2C8 isoenzyme), no evidence was obtained of montelukast inhibiting the CYP2C8 isoenzyme. Therefore, in clinical practice, the effect of montelukast on the CYP2C8-mediated metabolism of a number of drugs, incl. paclitaxel, rosiglitazone, repaglinide. In vitro studies have shown that montelukast is a substrate of the CYP2C8, 2C9 and 3A4 isoenzymes. Data from a clinical drug interaction study of montelukast and gemfibrozil (an inhibitor of both CYP2C8 and 2C9) demonstrate that gemfibrozil increases the effect of systemic exposure to montelukast by 4.4 times. Coadministration of itraconazole, a strong CYP3A4 inhibitor, with gemfibrozil and montelukast did not result in an additional increase in the effect of systemic exposure to montelukast. The effect of gemfibrozil on the systemic exposure of montelukast may not be considered clinically significant based on safety data when used at doses greater than the approved dose of 10 mg in adult patients (eg, 200 mg/day for adult patients for 22 weeks and up to 900 mg/day for no clinically significant adverse effects were observed in patients taking the drug for approximately one week). Thus, when co-administered with gemfibrozil, no dose adjustment of montelukast is required. Based on the results of in vitro studies, no clinically significant drug interactions are expected with other known CYP2C8 inhibitors (for example, with trimethoprim). In addition, co-administration of montelukast with itraconazole alone did not lead to a significant increase in the effect of systemic exposure to montelukast. Combination treatment with bronchodilators Singulair® is a reasonable addition to monotherapy with bronchodilators if the latter do not provide adequate control of bronchial asthma. After achieving a therapeutic effect from treatment with Singulair®, you can begin to gradually reduce the dose of bronchodilators. Combined treatment with inhaled GCS Treatment with Singulair® provides an additional therapeutic effect in patients using inhaled GCS. Once the condition has stabilized, you can begin a gradual reduction in the dose of GCS under the supervision of a physician. In some cases, complete abolition of inhaled corticosteroids is acceptable, but abrupt replacement of inhaled corticosteroids with Singulair® is not recommended.

Side effect

In general, Singulair® is well tolerated by patients. Side effects are usually mild and, as a rule, do not require discontinuation of the drug. The overall frequency of side effects when treated with Singulair® is comparable to their frequency when taking placebo. Children aged 2 to 5 years with bronchial asthma In clinical studies of the drug Singulair®, 573 patients aged 2 to 5 years took part. In a 12-week placebo-controlled clinical trial, the only adverse event (AE) assessed as drug-related occurring in >1% of Singulair-treated patients and more frequently than in placebo-treated patients was thirst. The differences in the incidence of this AE between the two treatment groups were not statistically significant. In total, in the studies, 426 patients aged 2 to 5 years were treated with Singulair® for at least 3 months, 230 for 6 months or longer, and 63 patients for 12 months or longer. With longer treatment, the AE profile did not change. Children aged 2 to 14 years with seasonal allergic rhinitis A 2-week placebo-controlled clinical trial using the drug Singulair® for the treatment of seasonal allergic rhinitis involved 280 patients aged 2 to 14 years . Patients took Singulair® 1 time/day in the evening and was generally well tolerated. The safety profile of the drug in children was similar to that of placebo. In this clinical study, there were no AEs that were considered drug-related, occurring in ≥1% of patients taking Singulair® and more frequently than in the placebo group. Children aged 6 to 14 years with bronchial asthma The safety profile of the drug in children was generally similar to the safety profile in adults and comparable to the safety profile of placebo. In an 8-week placebo-controlled clinical trial, the only AE assessed as drug related was observed in >1% of patients taking Singulair ®, and more often than in the group of patients taking placebo, there was a headache. The difference in frequency between the two treatment groups was statistically insignificant. In studies assessing the growth rate, the safety profile in patients of this age group corresponded to the previously described safety profile of the drug Singulair®. With longer treatment (more than 6 months), the AE profile did not change. Adults and children aged 15 years and older with bronchial asthma In two 12-week placebo-controlled clinical studies with a similar design, the only AEs assessed as drug-related were observed in ?1% of patients taking Singulair®, and more often than in the group of patients, Those taking placebo had abdominal pain and headache. The differences in the incidence of these AEs between the two treatment groups were not statistically significant. With longer treatment (for 2 years), the AE profile did not change. Adults and children aged 15 years and older with seasonal allergic rhinitis Patients took Singulair® 1 time / day in the morning or evening, in general the drug was well tolerated, the safety profile of the drug was similar safety profile to placebo. In placebo-controlled clinical trials, there were no AEs that were considered drug-related, occurring in ≥1% of patients taking Singulair®, or more frequently than in the placebo group. In the 4-week placebo-controlled clinical study, the safety profile of the drug was similar to that in the 2-week studies. The incidence of drowsiness when taking the drug in all studies was the same as when taking placebo. Adults and children aged 15 years and older with year-round allergic rhinitis Patients took Singulair® 1 time per day in the morning or evening, the drug was generally well tolerated. The drug's safety profile was similar to that observed in patients with seasonal allergic rhinitis and placebo. In these clinical studies, there were no reported AEs that were considered drug-related, occurring in ≥1% of patients taking Singulair®, and more often than in the group of patients taking placebo. The incidence of drowsiness when taking the drug was the same as when taking placebo. Pooled analysis of clinical trial results A pooled analysis of 41 placebo-controlled clinical trials was conducted (35 studies involving patients aged 15 years and older, 6 studies involving patients aged 6 to 14 years) using validated methods for assessing suicidality. Among the 9929 patients receiving Singulair® and the 7780 patients receiving placebo in these studies, 1 patient was identified as suicidal in the group of patients receiving Singulair®. There were no suicides, suicide attempts, or other preparatory acts indicative of suicidal behavior in any of the treatment groups. A separate pooled analysis was conducted of 46 placebo-controlled clinical trials (35 studies involving patients aged 15 years or older; 11 studies in patients aged 3 months to 14 years) to assess adverse behavioral effects. Among the 11,673 patients treated with Singulair and 8,827 patients treated with placebo in these studies, the percentage of patients experiencing at least one adverse behavioral effect was 2.73% among patients treated with Singulair and 2.27% among patients treated with placebo; the odds ratio was 1.12 (95% confidence interval [0.93; 1.36]). AEs registered during post-registration use of the drug Infectious and parasitic diseases: upper respiratory tract infections. From the blood coagulation system: increased tendency to bleeding. From the immune system: hypersensitivity reactions, incl. anaphylaxis; very rare (Contraindications - children under 2 years of age; - phenylketonuria; - hypersensitivity to the components of the drug. Use during pregnancy and breastfeeding. Clinical studies of the drug Singulair® in pregnant women have not been conducted. Singulair® should be used during pregnancy and breastfeeding only in cases where the expected benefit to the mother outweighs the potential risk to the fetus or child. During post-marketing use of Singulair®, the development of congenital limb defects was reported in newborns whose mothers took Singulair® during pregnancy. Most of these women were also taking other drugs for treatment bronchial asthma during pregnancy. A cause-and-effect relationship between taking Singulair® and the development of congenital limb defects has not been established. It is not known whether montelukast is excreted in breast milk. Since many drugs are excreted in breast milk, this must be taken into account when prescribing Singulair® to breastfeeding women mothers. Use in children For children aged 2 to 5 years with bronchial asthma and/or allergic rhinitis, the dose is 4 mg (1 tablet)/day.

Overdose

Symptoms of overdose were not detected during clinical studies of long-term (22 weeks) treatment with Singulair® in adult patients with bronchial asthma in doses up to 200 mg/day, or during short (about 1 week) clinical studies when taking the drug in doses up to 900 mg/day. days. There have been cases of acute overdose of Singulair® (taking at least 1000 mg/day) in the post-registration period and during clinical trials in adults and children. Clinical and laboratory data indicated comparable safety profiles of Singulair® in children, adults and elderly patients. The most common symptoms were thirst, drowsiness, vomiting, psychomotor agitation, headache and abdominal pain. These side effects are consistent with the safety profile of the drug Singulair®. Treatment: symptomatic therapy. There is no specific information on the treatment of overdose of Singulair®. There are no data on the effectiveness of peritoneal dialysis or hemodialysis with montelukast.

special instructions

The effectiveness of oral Singulair® in the treatment of acute attacks of bronchial asthma has not been established. Therefore, Singulair® tablets are not recommended for the treatment of acute attacks of bronchial asthma. Patients should be instructed to always carry emergency medications to relieve attacks of bronchial asthma (inhaled beta2-agonists). They should not stop taking Singulair® during an exacerbation of asthma and the need to use emergency medications (inhaled beta2-agonists) to relieve attacks. short-acting agonists). Patients with a confirmed allergy to acetylsalicylic acid and other NSAIDs should not take these drugs during treatment with Singulair®, since Singulair®, while improving respiratory function in patients with allergic bronchial asthma, however, cannot completely prevent the of them, NSAIDs cause bronchoconstriction. The dose of inhaled corticosteroids used simultaneously with the drug Singulair® can be gradually reduced under the supervision of a physician, however, an abrupt replacement of inhaled or oral corticosteroids with the drug Singulair® cannot be carried out. Neuropsychiatric disorders have been described in patients taking Singulair®. Given that these symptoms could be caused by other factors, it is unknown whether they are related to taking Singulair®. Physicians should discuss these side effects with patients and/or their parents/guardians. It is necessary to explain to patients and/or their guardians that if such symptoms occur, it is necessary to inform the attending physician. Reducing the dose of systemic corticosteroids in patients receiving antiasthmatic drugs, including leukotriene receptor blockers, was accompanied in rare cases by the appearance of one or more of the following reactions: eosinophilia , rashes, worsening pulmonary symptoms, cardiac complications and/or neuropathy, sometimes diagnosed as Churg-Strauss syndrome, systemic eosinophilic vasculitis. Although the cause-and-effect relationship of these adverse reactions with therapy with leukotriene receptor antagonists has not been established, when reducing the dose of systemic corticosteroids in patients receiving Singulair®, care must be taken and appropriate clinical monitoring must be carried out. Chewable tablets 4 mg contain aspartame, a source of phenylalanine. Patients with phenylketonuria should be informed that each 4 mg chewable tablet contains aspartame equivalent to 0.674 mg phenylalanine. Singulair® in the form of chewable tablets 4 mg is not recommended for use in patients with phenylketonuria. Effect on the ability to drive vehicles and operate machinery. This section does not apply to the drug Singulair® chewable tablets 4 mg, since it is intended for the treatment of children from 2 to 5 years. Thus, the information presented below relates to the active substance of the drug montelukast. Taking Singulair® is not expected to affect the ability to drive a car or use moving machinery. However, individual reactions to the drug may vary. Some side effects (such as dizziness and drowsiness), which have been reported to occur very rarely with Singulair®, may affect the ability of some patients to drive vehicles and operate machinery.

Dispensing conditions in pharmacies

On prescription

Interaction

Prescription with other drugs that are used for the prevention or long-term treatment of asthma is acceptable.

With caution, this drug should be prescribed together with blockers CYP ZA4, 2C9 and 2C8.

The systemic exposure of montelukast increases 4.4 times when combined with gemfibrozil. No dosage adjustment is required, but the doctor should consider the possibility of adverse reactions.

If treatment with bronchodilators is not effective, Singulair can be added to therapy. When the desired effect is achieved, the dose of bronchodilators can be gradually reduced.

The drug also allows for additional therapeutic effect in patients who use inhaled corticosteroids. When the condition has stabilized, the dose of corticosteroids can be reduced. But this must be done gradually and under the supervision of a specialist. In some cases, the appointment can be canceled completely. An abrupt change in therapy is not recommended.

special instructions

The effectiveness of the drug in the treatment of acute attacks of bronchial asthma has not been established, and therefore it is not recommended for use in such situations. Patients should always carry emergency medications to relieve asthma attacks (inhaled short-acting β2-agonists).

Taking Singulair is not stopped during an exacerbation of bronchial asthma and when emergency medications are prescribed to relieve attacks (short-acting inhaled β2-agonists).

If you have a confirmed allergy to ASA and other NSAIDs (non-steroidal anti-inflammatory drugs), you should not take these drugs during treatment with Singulair. Since it cannot completely prevent bronchoconstriction caused by NSAIDs, despite the improvement in respiratory function in allergic bronchial asthma.

When using inhaled corticosteroids simultaneously, their dose should be gradually reduced under the supervision of a physician; abrupt replacement with Singulair should not be carried out.

There are reports of the occurrence of psychoneurological disorders in patients taking the drug. Considering that other factors can contribute to the development of these symptoms, their connection with taking the drug has not been proven. Patients and their parents/guardians should be warned about these side effects and the need to report their occurrence to the doctor.

Reducing the dose of systemic corticosteroids in patients taking anti-asthma drugs (including leukotriene receptor blockers) is rarely accompanied by the occurrence of one or more reactions: systemic eosinophilic vasculitis, cardiac complications and/or neuropathy, sometimes diagnosed as Churg-Strauss syndrome, worsening of pulmonary symptoms, rash, eosinophilia. Although the cause-and-effect relationship of these side effects with the use of leukotriene receptor antagonists has not been established, when reducing the dose of systemic corticosteroids in patients receiving Singulair, caution should be exercised and appropriate clinical monitoring should be carried out.

Analogues of Singulair

The following analogues of Singulair are sold in pharmacies:

• Vanseir;
• Glemont;
• Lucast;
• Milukant;
• Moncasta;
• Montel;
• Single;
• Tevalukast.

All drugs have their own nuances of use. Analogues of Singulair should not be used without the appointment of a specialist. All of the above funds are quite expensive. But the price of Singulair analogues is noticeably lower than the drug described. Of these, Vanseir and Tevalukast are considered the most affordable.

Single or Singular – which is better?

Singlen is one of the most popular analogues of Singular. The last drug is too expensive for many, so they try to look for substitutes for it. Questions “Singlon or Singular – which is better?” can often be found on forums. Those who have tried both products write that they did not notice any difference. At the same time, Singlon is half the price.

Doctors report that there is still a difference in effectiveness and in most cases it is better to take Singulair, but if you need to replace it, then it is advisable to start taking Singlon.

Montelukast

Montelukast and its analogues are the active components of various products. The product looks like a dry white powder. It has good solubility. This component of drugs has bronchodilator effects.

It works in conjunction with mediator receptors activated in diseases of the lower respiratory tract , including bronchioles and bronchi.

• Description of the medication Montelukast
• Montelukast tablets and its analogues
• Montelukast: price and rules of use
• How to take Montelukast
• Montelukast - analogues
• Singulair is the most popular analogue
• Montelar is a good and inexpensive substitute
• Ektalust - a cheap analogue
• Monler tablets
• Other similar products
• Reviews about the drug Montelukast
• Features of the use of the drug Montelukast

Most often, a person, feeling unwell, goes to the pharmacy on his own and purchases various antiviral drugs. In this case, the buyer is faced with the choice of buying this drug or purchasing its analogue. Medicine Montelukast, its analogues, use, and dosage instructions.

Description of the medication Montelukast

After entering the stomach, the drug is quickly absorbed, becoming most effective a few hours after administration. This medicine is metabolized in the liver and eliminated by the urinary system. Thanks to Montelukast, the following action occurs:

1. Reducing swelling and spasms of smooth muscles.
2. The functioning of the vessels of the respiratory system (lower as well as upper sections) is normalized.
3. The transportation of mucus improves due to a decrease in its production.

The drug Montelukast can be presented in two forms . In the form of chewable tablets and film-coated pills for oral administration. The components of Montelukast in one tablet may be different, so you should carefully read the instructions before purchasing the drug.

Montelukast tablets and its analogues

The instructions for use of the drug describe this drug as a bronchodilator and antileukotriene antibiotic. It is produced in the form of chewable tablets that contain 5 or 10 mg of active ingredients.

Montelukast: price and rules of use

Montelukast tablets will cost 700 rubles. The price of the medicine will depend on how much of the drug you decide to purchase. So, 28 tablets of 5 grams each can be purchased for 900 rubles.

Before you start searching for similar drugs, you should find out the purpose of this medicine. Montelukast is prescribed to people suffering from bronchial asthma for its treatment as well as prevention.

And also, tablets are used for rhinitis , if it is allergic in nature. The drug will cope well with bronchospasms during increased physical activity. Tablets are strictly prohibited for persons who are highly sensitive to this substance, as well as children under 2 years of age and pregnant women.

If the use of tablets must be carried out during breastfeeding, then lactation must be stopped . If the dosage is incorrectly selected or the instructions are not followed, the medicine may cause:

• upset stomach and digestive system of the body;
• headache and dizziness;
• airway congestion and swelling.

In addition to all this, the drug can cause central nervous system reactions, allergies , disruption of the circulatory and cardiac systems, as well as a flu-like state of the patient.

How to take Montelukast

More detailed information about the rules for using the medicine can be found in its instructions. For the treatment of bronchial asthma, usually take 10 mg of the drug per day (preferably before bedtime). For preventive purposes, the dose of the drug can reach up to 5 mg per day.

When treating allergic rhinitis, you should take Montelukast 4 mg-10 mg per day (the dosage of the drug will depend on the degree of the disease and the assessed effectiveness of the drug).

The number of days during which the drug should be taken is determined by the attending physician , taking into account all the features of the development of the disease. Montelukast tablets may be prescribed in conjunction with corticosteroids and bronchodilators.

Montelukast - analogues

If the use of Montelukast is contraindicated for you for some reason, then you should select analogues of this drug together with your doctor.

Do not choose analogues yourself and do not give medicines to children without a pediatrician’s prescription .

If the pharmacy does not have this drug, then you can look for its substitutes, similar in composition to the original:

• Singular.
• Ektalust.
• Montelar.
• Montclair.
• Single.

Sometimes the reason a buyer chooses other manufacturers is savings. Finding cheap substitutes for Montelukast tablets is not difficult. What drugs can save the consumer money and produce the desired effect?

Singulair is the most popular analogue

This product is also usually produced in the form of chewable tablets. One tablet contains about 4, 5 or 10 mg of active ingredient. We can say that the Singulair analogue is not exactly cheap. So, 5 mg tablets in an amount of 14 pieces will have a price of 1200 rubles.

Unlike Montelukast, which is produced in Russia, Singulair originates in America. This drug can be used during pregnancy and even during breastfeeding. But the manufacturer warns that you should still consult a doctor before using the drug.

Each tablet of the drug contains a substance - aspartame , so patients with phenylketonuria should be warned about this in advance. This medicine should not be used to relieve acute bronchial asthma.

Montelar is a good and inexpensive substitute

If your goal is to save on the purchase of a medication, then Montelar will definitely appeal to you. The dosages of the product are the same as its predecessors.

The package contains 14 tablets weighing 5 mg and cost about 650 rubles . It will be half the price of Singulair. The manufacturer of the medicine is the country of Switzerland.

The tablets are strictly contraindicated for people who are highly intolerant to the components of the drug, as well as those suffering from phenylketonuria. And also, it should not be given to children under six years of age.

Based on reviews of the medicine, you can see that it rarely causes side effects , unlike previous remedies. Side effects may include abdominal pain, allergies, and flu-like symptoms. The disadvantage of Montelar is its inability to replace inhaled drugs for emergency use.

Ektalust - a cheap analogue

So, this remedy is the most accessible of Montelukast analogues. A package of Ektalust contains 14 tablets of 5 mg each, the drug costs about 500 rubles. The tablets contain the active ingredient – ​​montelukast.

The drug can cure bronchial asthma, aspirin-induced asthma, and can also prevent bronchospasms and shortness of breath during power exercise. Ektalust tablets cope well with night attacks of rhinitis.

The product is prohibited for use in children under 2 years of age, as well as in children under 6 years of age in an amount of 5 mg. To treat bronchial asthma, Ektalust should be taken in the evening. If the patient has allergic rhinitis, then it is consumed an hour before meals or two after it. The drug can be used at any time of the day.

Monler tablets

Analogues of Montelukast include Monler. The cost of Monler tablets will be about 700 rubles for 14 tablets weighing 5 mg. This is slightly more expensive than the cost of the initial medicine. This drug has no special properties or signs.

It should be noted that this drug has a good effect on the body of patients . Thus, practice has shown that the treatment Monler very rarely leads to side effects. The tablets quickly penetrate the body and the effect of treatment begins to appear after just a few days of taking the medicine.

Other similar products

Other Montelukast analogues may have other components in their composition, but still have the same effect on the patient’s body and treat bronchial asthma.

Bronchodilator drugs allow you to relax smooth muscles, relieve muscle spasms, ease breathing and expand the bronchi themselves.

These medications can be used alone or in combination with other medications to treat asthma. You can find the following analogue products in pharmacies:

1. Omnitus.
2. Erespal.
3. Ascoril.
4. Pertussin and so on.

Substitutes for the original remedy should be chosen, taking into account the individual characteristics of the body and the stages of development of the disease.

Reviews about the drug Montelukast

Customer reviews of this drug are quite high. A large number of people after using the product are satisfied with the result. Montelukast really helps suppress attacks of bronchial asthma and ease breathing with allergic rhinitis.

Chewable pills have a fairly pleasant taste , so the child can easily chew the pills on his own. After all, not all children are able to take bitter-tasting medications.

One of the advantages of Montelukast is the ability to use it for a long time. Thus, the components of corticosteroids cannot be used for a long time, since the time of treatment with this drug is strictly limited.

Some patients switched to other substitute drugs for several reasons. For example, during pregnancy, bronchial asthma does not stop, but, on the contrary, during this time the disease can only increase. That is why pregnant women should take medications to prevent the occurrence of pathologies in the body.

For the treatment of pregnant women, it is recommended to use the medicine Singulair . If treatment occurs in a child under 2 years of age, then other substitutes for Montelukast tablets should be used without using structural drugs.

My daughter has been using the product since she was 2.5 years old, following a prescription from an allergist (bronchial asthma, hay fever, food and household allergies). According to the results of use, it is not inferior to Singular and Montelar. The drug is well tolerated and does not cause any side effects.

Irina. Moscow city.

Good afternoon My nephew had asthma, and we have long wanted to find a good drug at an affordable price. Treatment of asthma must take a long time; the original drug is quite expensive. Therefore, the pharmacy advised me to purchase Montelast for 98 tablets. The effect of the drug remains the same, but the price is much lower.

Ksenia. Saint Petersburg.

The drug has been used by my eldest daughter since she was 5 years old as prescribed by an allergist due to hay fever. We were recently prescribed Singulair. The difference between Montelast and Singulair is small, and the effectiveness of the two drugs remains high.

Julia. Norilsk.

Features of the use of the drug Montelukast

Now you know a little more about the drug Montelukast. Instructions for use of the product, its price, analogues and reviews - all this should be paid attention to before purchasing the medicine.

The manufacturer of the drug recommends using it only with a pre-written prescription . Despite this, the medicine is not prohibited and is freely available in any pharmacy. Many pharmacies and enterprises produce the drug and its analogues for sale without the permission of the attending physician.

If you are a person who is used to self-medicating, then before using the medicine, carefully read its instructions and characteristics. During the course of treatment with the drug, you should carefully monitor your well-being and body reactions.

As buyers say, the drug begins to act and bring the desired effect within a day after the first dose. The manufacturer also confirms this information.

If you do not observe an improvement in your condition after three days of taking the drug, then you should immediately seek help from a doctor . Do not increase the dose of the drug yourself, as this may lead to negative consequences.

In case of bronchial disease, the patient should be regularly examined in a clinic , take preventive medications and have emergency medications nearby. This type of disease cannot be left without medical attention and should be treated negligently. After some time, the patient’s body will feel much better and will begin to recover.

Reviews about Singulair

Reviews about Singulair on forums are mostly positive. Reports of side effects are extremely rare.

Reviews from parents about Singulair indicate that it is a very effective fast-acting remedy that is suitable for children of different ages. It is especially emphasized that the medicine is safe for health. So for those who are wondering whether this drug is hormonal or not, doctors and those who have used it in practice clearly answer that it is non-hormonal. On the contrary, in some cases it can replace inhaled corticosteroids, which is especially important if the medicine must be given to children.

Reviews from doctors indicate that this remedy is often prescribed for various respiratory diseases. Experts and patients believe that the high price of the drug is absolutely justified.

Indications for use

Singulair is prescribed to patients over 2 years of age for diseases accompanied by airway obstruction. Instructions for use contain a complete list of medical indications:

• bronchial asthma (with hypersensitivity to acetylsalicylic acid);
• prevention of bronchospasm (during high physical exertion);
• prevention of bronchial asthma in childhood;
• treatment of allergic rhinitis (as part of complex therapy).